Cell therapy (CAR-NK) · Kills target cells, directed at CD19 · developed by Nkarta
Belacabnagene franleucel is an allogeneic, off-the-shelf natural killer cell therapy engineered to express membrane-bound IL-15 and a CD19-directed chimeric antigen receptor with OX40 and CD3-zeta signaling domains. It targets CD19-expressing cells and is being studied in lupus nephritis and primary membranous nephropathy.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06557265 | Phase 1/2 | Lupus Nephritis | Recruiting | NKTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Lupus NephritisPrimary Membranous Nephropathy
Updated Oct 25, 2026. Something wrong or missing? Report it on the NKTX page.
See NKTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NKTX catalysts and pipeline →